India Pharma Outlook Team | Monday, 16 November 2026
The Sun Pharma-Organon deal marks a major step in the pharmaceutical company's global expansion, but financing the USD 11.75 billion acquisition presents an equally important challenge.
Sun Pharmaceutical Industries announced its proposed acquisition of US healthcare company Organon & Co in April 2026, using an 18-month bridge loan to support the transaction.
Now, Sun Pharma is moving towards longer-term financing as it prepares to refinance part of this temporary borrowing.
This financing strategy highlights how Sun Pharma plans to manage acquisition debt while maintaining financial flexibility.
Sun Pharma's proposed USD 4 billion syndicated loan will help to replace a part of the bridge financing that supported its acquisition of Organon.
The Organon deal financing strategy therefore marks a transition from temporary acquisition borrowing towards longer-term debt management.
Also Read: 5 Women Leaders Driving India's Pharma and Healthcare Innovation
Sun Pharma is exploring multiple funding avenues to reduce its reliance on bridge financing.
The Organon deal requires a balanced funding strategy that combines refinancing with additional capital options. Multiple financing avenues could help the company manage repayment obligations while protecting its financial flexibility.